|Bid||129.92 x 900|
|Ask||130.36 x 800|
|Day's range||129.36 - 131.19|
|52-week range||121.00 - 148.99|
|Beta (3Y monthly)||0.73|
|PE ratio (TTM)||21.61|
|Earnings date||15 Oct 2019|
|Forward dividend & yield||3.80 (2.92%)|
|1y target est||149.35|
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Karyopharm (KPTI) signs royalty agreement with HealthCare Royalty Partners for up to $150 million to fund Xpovio's commercialization and development.
J&J's (JNJ) sBLA seeking approval for Tremfya for active psoriatic arthritis is based on data from the phase III DISCOVER 1 and 2 studies.
The FDA assigns a Fast Track status to AstraZeneca's (AZN) Farxiga to reduce the risk of cardiovascular death or worsening of heart failure in adult patients with HFrEF and HFpEF.
Amgen's (AMGN) phase III study on Kyprolis in combination with dexamethasone and J&J's Darzalex meets the goal of progression-free survival for treating relapsed or refractory multiple myeloma.
CMR Surgical, a five-year-old medical robotics company based in Cambridge, has raised £195m in a funding round that pushed the value of the company to more than £1bn ahead of the launch of its first product. The Series C financing — the largest in Europe‘s medical technology sector, according to CMR — will “fully fund the global commercialisation of the business”, said Martin Frost, chief executive. Versius is designed to provide surgeons with multiple robotic arms to carry out a range of keyhole or minimal access procedures.
Hoy Health launched less than two years ago, but sees strong growth potential in paving the way to the Latin American health care market.
Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.
J&J (JNJ) announces superiority of its multiple sclerosis candidate, ponesimod compared to Sanofi's Aubagio in patients with relapsing form of the disease.
Mallinckrodt's (MNK) shares gain as it agrees to sell its contract manufacturing unit to raise cash to settle liabilities from various opioid litigations.
Lexicon Pharmaceuticals (LXRX) settles with Sanofi related to termination of their alliance for development of Zynquista in type I and type II diabetes.
Theravance's (TBPH) investigational JAK inhibitor TD-8236 demonstrates favorable results from a phase I study for treating inflammatory lung diseases.
How far off is Johnson & Johnson (NYSE:JNJ) from its intrinsic value? Using the most recent financial data, we'll take...
Allergan (AGN) settles with two Ohio plaintiffs for $5 million. Merck's (MRK) Keytruda, Roche's (RHHBY) Tecentriq and J&J's (JNJ) Stelara get EU approval for expanded use.